| Title: | Cancer-associated thrombosis by cancer sites and inherited factors in a prospective population-based cohort |
| Journal: | Thrombosis Research |
| Published: | 26 Jun 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37419004/ |
| DOI: | https://doi.org/10.1016/j.thromres.2023.06.023 |
| Citations: | 2 (2 in last 2 years) as of 8 Aug 2024 |
Publication 11596
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Cancer-associated thrombosis (CAT) is common and associated with mortality. We estimated CAT rate by cancer sites and inherited factors among cancer patients from the UK Biobank (N =70,406). The 12-month CAT rate after cancer diagnosis was 2.37% overall but varied considerably among cancer sites. Among the 10 cancer sites classified as 'high-risk' of CAT by the National Comprehensive Cancer Network guidelines, 6 had CAT rate <5%. In contrast, 5 cancer sites classified as 'average-risk' by the guidelines had CAT rate >5%. For inherited risk factors, both known mutation carriers in two genes (F5/F2) and polygenic score for venous thromboembolism (VTE) (PGSVTE) were independently associated with increased CAT risk. While F5/F2 identified 6% patients with high genetic-risk for CAT, adding PGSVTE identified 13 % patients at equivalent/higher genetic-risk to CAT than that of F5/F2 mutations. Findings from this large prospective study, if confirmed, provide critical data to update guidelines for CAT risk assessment.</p>
19 Authors
- Zhuqing Shi
- Jun Wei
- Andrew S Rifkin
- Chi-Hsiung Wang
- Liana K Billings
- Jonathan S H Woo
- Mark S Talamonti
- Tilley Jenkins Vogel
- Elena Moore
- Bruce E Brockstein
- Janardan D Khandekar
- Henry M Dunnenberger
- Peter J Hulick
- David Duggan
- S Lilly Zheng
- Cheong Jun Lee
- Brian T Helfand
- Alfonso J Tafur
- Jianfeng Xu
1 Application
| Application ID | Title |
|---|---|
| 50295 | Validity and performance of inherited risk assessment for common diseases using polygenic risk score, family history, and high-penetrance genes |
Enabling scientific discoveries that improve human health